In vitro and in vivo experiments demonstrated that Bortezomib successfully shuts-down the NF-kB pathway and significantly induces BPDCN cell apoptosis, providing a potential new therapeutic option for BPDCN patients [2,81]. Here, NFKB1 is linked to CD4+/CD56+ hematodermic neoplasm.